NOD-like receptor X1 functions as a tumor suppressor by inhibiting epithelial-mesenchymal transition and inducing aging in hepatocellular carcinoma cells

Table 3 Multivariate analyses of factors associated with survival and recurrence

Clinical and pathologic indexes		OS		RFS
Clinical and pathologic indexes		HR (95% CI)	P	HR (95% CI)	P
HBsAg	(Positive vs. negative)	2.26 (1.16,4.41)	0.017	1.14 (0.53,2.43)	0.740
AFP (ng/mL)	(> 400 vs. ≤ 400)	–	–	1.12 (0.88,1.43)	0.360
Tumor number	(Multiple vs. single)	0.97 (0.49,1.91)	0.923	1.73 (1.02,2.95)	0.043
Tumor encapsulation	(Complete vs. none)	0.77 (0.59,0.99)	0.050	0.85 (0.67,1.09)	0.199
Edmondson stage	(I-II vs. II-IV)	–	–	0.73 (0.56,0.95)	0.018
BCLC stage	(0-A vs. B-C)	0.57 (0.28,1.14)	0.112	0.83 (0.48,1.46)	0.523
PVTT	(None vs. yes)	0.72 (0.55,0.94)	0.018	0.90 (0.70,1.17)	0.439
NLRX1	(Positive vs. negative)	0.51 (0.39,0.67)	0.000	0.58 (0.45,0.76)	0.000

Abbreviations: AFP α-fetoprotein, BCLC Barcelona Clinic Liver Cancer, CI confidence interval, HR hazard ratio, GGT gamma-glutamyl transpeptidase, HBsAg hepatitis B virus surface antigen, NLRX1 nucleotide-binding oligomerization domain-like receptor X1, OS overall survival, PVTT portal vein tumor thrombus, RFS recurrence-free survival

ISSN: 1756-8722